Seminars in Pediatric Neurology
Volume 17, Issue 2 , Pages 100-104 , June 2010

Headaches and Hormones

  • Ann Pakalnis, MD

      Affiliations

    • Columbus Childrens' Hospital, Columbus, OH
    • ,
  • Jack Gladstein, MD

      Affiliations

    • University of Maryland School of Medicine, Baltimore, MD
    • Corresponding Author InformationAddress reprint requests to Jack Gladstein, MD, University of Maryland Hospital, 22 South Greene Street Room N5W69, Baltimore, MD 21201

References 

  1. Gunner KB, Smith HD. Practice guideline and management of migraine headaches in children and adolescents. J Pediatr Health Care. 2007;21:327–332
  2. Bigal M, Liberman JN, Lipton RB. Age-dependent prevalence and clinical features of migraine. Neurology. 2006;67:246–251
  3. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: Data from the American Headache Study II. Headache. 2001;41:646–657
  4. Le Kesche L, Manal LA, Grangoholt MT, et al. Relationship of pain and symptoms to pubertal development in adolescents. Pain. 2005;118:201–209
  5. Kröner-Herwig B, Vath N. Menarche in girls and headache—A longitudinal analysis. Headache. 2009;49:860–867
  6. Slater S, Crawford MJ, Kubbouche MA, et al. Effects of gender and age on pediatric headache. Cephalalgia. 2009;29:969–973
  7. Abu-Arafeh I, Russell G. Prevalence of headache and migraine in schoolchildren. BMJ. 1995;309:765–769
  8. Martin VT, Behbehani M. Ovarian hormones and migraine headache: Understanding mechanisms and pathogenesis—Part 1. Headache. 2006;46:3–23
  9. Martin VT, Behbehani M. Ovarian hormones and migraine headache: Understanding mechanisms and pathogenesis—Part 2. Headache. 2006;46:365–386
  10. Finkelstein JW. Endocrine Physiology at Puberty in Comprehensive Adolescent Health Care. St. Louis, MO: Mosby Year Book; 1998;
  11. Lay CL, Broner SW. Migraine in women. Neurol Clin. 2009;27:503–511
  12. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295:1549–1555
  13. Li C, Ford ES, McGuire LC, et al. Increasing trends in waist circumference and abdominal obesity among U.S. adults. Obesity. 2007;15:216–224
  14. Bigal ME, Lipton RB. Obesity is a risk factor for transformed migraine but not chronic tension type headache. Neurology. 2006;67:252–257
  15. Bigal ME, Liberman JN, Lipton RB. Obesity and migraine: A population study. Neurology. 2006;66:545–550
  16. Horev A, Wirguin I, Lantsberg L, et al. A high incidence of migraine with aura among morbidly obese women. Headache. 2005;45:936–938
  17. Hershey AD, Powers SW, Nelson TD, et al. Obesity in the pediatric headache population: A multicenter study. Headache. 2009;49:170–177
  18. Bigal ME, Lipton RB, Holladn PR, et al. Obesity, migraine and chronic migraine, possible mechanisms of interaction. Neurology. 2007;68:1851–1861
  19. International Headache Society: The International Classification of Headache Disorders (ed 2). Cephalalgia. 2004;24(suppl 1):1–151
  20. Martin VT, Behbehani M. Ovarian hormones and migraine headache: Understanding mechanisms and pathogenesis. Part 1. Headache. 2006;46:3–23
  21. Crawford MJ, Lehman L, Slater S, et al. Menstrual migraine in adolescents. Headache. 2009;49:341–347
  22. Al-Walli NS. Treatment of menstrual migraine with prostaglandin synthesis inhibitor mefaminic acid: Double blind study with placebo. Eur J Med Res. 2000;5:176–182
  23. Newman LC, Lipton RB, Lay CL, et al. A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. Neurology. 1998;51:307–309
  24. Newman LC, Mannix LK, Landy S, et al. Naratriptan as short-term prophylaxis of menstrually associated migraine: A randomized double-blind, placebo-controlled study. Headache. 2001;41:248–256
  25. Silberstein SD, Elkin AH, Schreiber C, et al. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology. 2004;63:261–269
  26. Tuchman MM, Hee A, Emeribe U, et al. Oral zolmitriptan in the short-term prevention of menstrual migraine: A randomized, placebo-controlled study. CNS Drugs. 2008;22:877–886
  27. Silberstein SD, Bradley K. DHE-forty-five in the prophylaxis of menstrually related migraine. Cephalalgia. 1996;16:371
  28. Sulak PJ, Cressman BE, Waldrop E, et al. Extending the duration of active oral contraceptive pills to mange hormone withdrawal symptoms. Obstet Gynecol. 1997;89:179–183
  29. Lay CL, Broner SW. Migraine in women. Neurol Clin. 2009;27:503–511
  30. Burkman RT, Collins JA, Shulman LP, et al. Current perspectives on oral contraceptive use. Am J Obstet Gynecol. 2001;185:504–512
  31. International Headache Society: International Classification of Headache Disorders (ed 2). Cephalalgia. 2004;24(suppl 1):9–160
  32. Sulak P, Willis S, Kuehl T, et al. Headaches and oral contraceptives: Impact of eliminating the standard 7-day placebo interval. Headache. 2007;47:27–37
  33. Calhoun A, Ford S. Elimination of menstrual-related migraine beneficially impacts chronification and medication overuse. Headache. 2008;48:1186–1193
  34. Allais G, Gabellari I, Mana O, et al. Migraine and stroke: The role of oral contraceptives. Neurol Sci. 2008;29:S12–S14
  35. Allais G, Gabellari I, De Lorenzo C, et al. Oral contraceptives in migraine. Expert Rev Neurother. 2009;9:381–393
  36. Galvin JA, Van Stavern GP. Clinical characterization of idiopathic intracranial hypertension at the Detroit Medical Center. J Neurol Sci. 2004;223:157–160
  37. Wall M. Idiopathic intracranial hypertension. Curr Neurol Neurosci Rep. 2008;8:87–93
  38. Ooi LY, Walker BR, Bodkin A, et al. Idiopathic intracranial hypertension: Can studies of obesity provide the key to understanding pathogenesis?. Br J Neurosurg. 2008;22:187–194
  39. Sinclair AJ, Ball AK, Burdon MA, et al. Exploring the pathogenesis of IIH: An inflammatory perspective. J Neuroimmunol. 2008;201:212–220
  40. Donaldson JO. Cerebrospinal fluid hypersecretion in pseudotumor cerebri. Trans Am Neurol Assoc. 1979;104:196–198
  41. Ball AK, Clarke CE. Idiopathic intracranial hypertension. Lancet Neurol. 2006;5:433
  42. Orefice G, Celentano L, Scaglione M, et al. Radioisotope cisternography in benign intracranial hypertension of young obese women (A seven-case study and pathogenic suggestions). Acta Neurol. 1992;14:39–50
  43. Janny P, Chazal J, Colnet G, et al. Benign intracranial hypertension and disorders of CSF absorption. Surg Neurol. 1981;15:168–174
  44. King JO, Mitchell PJ, Thomson KR, et al. Manometry combined with cervical puncture in idiopathic intracranial hypertension. Neurology. 2002;58:26–30
  45. Goodwin J. Recent developments in idiopathic intracranial hypertension. Semin Ophthalmol. 2003;18:181–189
  46. Jennum P, Borgesen SE. Intracranial pressure and obstructive sleep apnea. Chest. 1989;95:279–283
  47. Sugerman H, Windsor A, Bessos M, et al. Intra-abdominal pressure sagittal abdominal diameter and obesity comorbidity. J Intern Med. 1997;241:71–79
  48. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005;115:911–919
  49. Hotamisgilil GS, Shargill NS, Speigelman BM. Adipose expression of tumor necrosis factor –alpha: Direct role in obesity-linked insulin resistance. Science. 1993;259:87–91
  50. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112:1796–1808
  51. Ostlund RE, Yang JW, Klein S, Gingerich R, et al. Relation between plasma leptin concentration and body fat, gender, diet, age, and metabolic covaries. J Clin Endocrinol Metab. 1996;81:3909–3913

PII: S1071-9091(10)00036-7

doi: 10.1016/j.spen.2010.04.007

Seminars in Pediatric Neurology
Volume 17, Issue 2 , Pages 100-104 , June 2010

Article Tools